219 related articles for article (PubMed ID: 29675860)
1. Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
Masuda K; Tokito T; Azuma K; Yanagida E; Nakamura M; Naito Y; Matsuo N; Ishii H; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2018 Jun; 9(6):754-757. PubMed ID: 29675860
[TBL] [Abstract][Full Text] [Related]
2. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
[TBL] [Abstract][Full Text] [Related]
3. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
4. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Naidoo J; Sima CS; Rodriguez K; Busby N; Nafa K; Ladanyi M; Riely GJ; Kris MG; Arcila ME; Yu HA
Cancer; 2015 Sep; 121(18):3212-3220. PubMed ID: 26096453
[TBL] [Abstract][Full Text] [Related]
5. A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Xing K; Zhou X; Zhao X; Sun S; Luo Z; Wang H; Yu H; Wang J; Chang J; Wu X; Hu A
Med Oncol; 2014 Jul; 31(7):36. PubMed ID: 24908064
[TBL] [Abstract][Full Text] [Related]
6. EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
Zhu YC; Wang WX; Xu CW; Song ZB; Du KQ; Chen G; Lv TF; Song Y
Lung Cancer; 2018 Jan; 115():131-134. PubMed ID: 29290255
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report.
Yazaki T; Kimoto M; Minagawa A; Maruno T; Yamanaka M; Sonehara K; Hama M; Nakamura T; Kanda S; Hanaoka M; Hachiya T
Am J Case Rep; 2024 Jun; 25():e943466. PubMed ID: 38822519
[TBL] [Abstract][Full Text] [Related]
9. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
[TBL] [Abstract][Full Text] [Related]
10. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
Venugopalan A; Lee MJ; Niu G; Medina-Echeverz J; Tomita Y; Lizak MJ; Cultraro CM; Simpson RM; Chen X; Trepel JB; Guha U
Oncotarget; 2016 Aug; 7(34):54137-54156. PubMed ID: 27494838
[TBL] [Abstract][Full Text] [Related]
11. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
Carney BJ; Rangachari D; VanderLaan PA; Gowen K; Schrock AB; Ali SM; Costa DB
Lung Cancer; 2017 Dec; 114():108-110. PubMed ID: 28870636
[No Abstract] [Full Text] [Related]
12. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
Li S; Zhao J; Wang Q
J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
[No Abstract] [Full Text] [Related]
13. Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Wu K; Guo C; Li R
Medicine (Baltimore); 2019 May; 98(18):e15489. PubMed ID: 31045832
[TBL] [Abstract][Full Text] [Related]
14. Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.
Liang JY; Tong F; Gu FF; Liu YY; Zeng YL; Hong XH; Zhang K; Liu L
Medicine (Baltimore); 2017 May; 96(21):e6985. PubMed ID: 28538405
[TBL] [Abstract][Full Text] [Related]
15. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Ibrahim U; Saqib A; Atallah JP
Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
17. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Hata A; Katakami N; Yoshioka H; Kunimasa K; Fujita S; Kaji R; Notohara K; Imai Y; Tachikawa R; Tomii K; Korogi Y; Iwasaku M; Nishiyama A; Ishida T
J Thorac Oncol; 2013 Jan; 8(1):89-95. PubMed ID: 23242440
[TBL] [Abstract][Full Text] [Related]
18. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
[TBL] [Abstract][Full Text] [Related]
19. Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.
Jin LL; Wu ZZ; Wang YL; Chen DS; Li S; Xiao M; Zhao X
Invest New Drugs; 2021 Oct; 39(5):1419-1421. PubMed ID: 33835358
[TBL] [Abstract][Full Text] [Related]
20. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
Čoupková H; Vyzula R
Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]